Tags |
|
|
Links |
|
|
Actual - Cypher Stent Lawyer - Drug Coated Stent Warnings - Heart Stent Injury
Cypher Stents Allegedly Linked to Fatalities
A Cleveland Clinic study released findings on Novem
A Cleveland Clinic study released findings on Novem
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ber 29, 2006 that indicated that the drug-coated Johnson & Johnson Cypher Stent is four to five t
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
mes more likely to cause serious cardiovascular problems than are non-coated stents.
Stents are
Stents are
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
esh wire tubes that doctors used to hold open arties after angioplasties. The Cypher Stent, appr
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ved by the Food and Drug Administration in 2003, emits a drug called Sirolimus that prevents recl
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
sure of the artery after the angioplasty balloon clears out any blockage. Some doctors believe t
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
at the drug works by preventing the regrowth of the coating that grows in the blood vessel around
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
the stent that can contribute to further clots.
There are over 800,000 angioplasties performed i
There are over 800,000 angioplasties performed i
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
the United States each year to remove blockages in arteries. Between 15 and 30 % of all these p
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ocedures will become clogged again, requiring further angioplasties or other procedures.
The FDA
The FDA
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
began to receive complaints about the Cypher Stent soon after it was released. It has been alleg
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
edly linked to hundreds of serious cases of blood clots, thrombosis, strokes, and heart attacks,
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
nd 60 people have died due to complications caused by the Cypher Stent. In fact, there were more
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
than 290 people that suffered blood clot-related complications within the first 30 days after the
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
received the devices.
Furthermore, the FDA also received more than 50 reports of severe allergi
Furthermore, the FDA also received more than 50 reports of severe allergi
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
reactions from the Sirolimus coating on the stent. Some people needed serious medical or surgic
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
l intervention due to these reactions, and some people even died due to complications.
There are
There are
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
thousands of potential people affected by this defective medical device, but it is unknown how ma
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
y people will suffer serious and potentially life-threatening complications. People with Cypher
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
tents should consult their doctors immediately and discover their options to protect their safety
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.actual.org.ua/article/127255/actual-Cypher-Stent-Lawyer--Drug-Coated-Stent-Warnings--Heart-Stent-Injury.html">Cypher Stent Lawyer - Drug Coated Stent Warnings - Heart Stent Injury</a>
BB link (for phorums):
[url=http://www.actual.org.ua/article/127255/actual-Cypher-Stent-Lawyer--Drug-Coated-Stent-Warnings--Heart-Stent-Injury.html]Cypher Stent Lawyer - Drug Coated Stent Warnings - Heart Stent Injury[/url]
Related Articles:
Home Buying 101 -- How's Your Credit?
Bookmark it:
|